$6.48
0.15% yesterday
Nasdaq, May 20, 09:47 pm CET
ISIN
US89532M1018
Symbol
TRVI
Sector
Industry

Trevi Therapeutics, Inc. Stock price

$6.47
+0.45 7.48% 1M
+3.70 133.57% 6M
+2.35 57.04% YTD
+3.64 128.62% 1Y
+4.22 187.56% 3Y
+3.77 139.63% 5Y
-1.42 18.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.02 0.31%
ISIN
US89532M1018
Symbol
TRVI
Sector
Industry

Key metrics

Market capitalization $658.29m
Enterprise Value $555.99m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 6.50
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-51.09m
Cash position $103.26m
EPS (TTM) EPS $-0.45
P/E forward negative
Short interest 8.18%
Show more

Is Trevi Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Trevi Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Trevi Therapeutics, Inc. forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Trevi Therapeutics, Inc. forecast:

Buy
100%

Financial data from Trevi Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.15 0.15
7% 7%
-
-0.15 -0.15
7% 7%
-
- Selling and Administrative Expenses 12 12
18% 18%
-
- Research and Development Expense 38 38
40% 40%
-
-51 -51
34% 34%
-
- Depreciation and Amortization 0.15 0.15
7% 7%
-
EBIT (Operating Income) EBIT -51 -51
34% 34%
-
Net Profit -47 -47
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about Trevi Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Trevi Therapeutics, Inc. Stock News

Neutral
PRNewsWire
about 17 hours ago
Results of analyses presented at an investor meeting during the American Thoracic Society 2025 International Conference NEW HAVEN, Conn. , May 20, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fib...
Neutral
Seeking Alpha
10 days ago
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Chief Financial Officer James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Faisal Khurshid - Leerink Annabel Samimy - Stifel Leland Gersh...
Neutral
PRNewsWire
12 days ago
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn.
More Trevi Therapeutics, Inc. News

Company Profile

Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.

Head office United States
CEO Jennifer Good
Employees 26
Founded 2011
Website www.trevitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today